This trial is evaluating whether Umbralisib will improve 1 primary outcome and 2 secondary outcomes in patients with Chronic Lymphocytic Leukemia (CLL). Measurement will happen over the course of 12 months.
This trial requires 84 total participants across 3 different treatment groups
This trial involves 3 different treatments. Umbralisib is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The cure of leukemia is a long, sometimes frustrating and frustrating process, and can be a boon for the patient's mind and for the medical community. However, many of the issues related to cure are less clear-cut than we might first believe. If we are to move to the field of cure we should learn to differentiate between the cure of "the disease" and the cure of a patient. This article discusses the different levels of cure as it applies to the many patients with leukemia." - Anonymous Online Contributor
"Symptoms of leukemia include weight loss, tiredness, malaise, anemia, and fatigue. Fever and low white blood cell count also occur. Some symptoms may be indicative of other conditions, such as infections with the Epstein-Barr virus." - Anonymous Online Contributor
"Leukemia is cancer of the bone marrow that most often occurs in adults with the typical symptoms of fever, weight loss, and easy bruising and bleeding. It is now well understood that leukemia results from the abnormal proliferation of blood-forming or leukemic cells, most commonly precursor T lymphocytes." - Anonymous Online Contributor
"Many patients with leukemia receive treatments for their cancer. There are no established guidelines for how these treatments should be administered. Treatment may involve surgery or chemi-therapy to control the cancer and to help the patient or their family manage side effects of these treatments.\n\nThere are many factors that determine whether the cancer progresses. Some factors are: \n\nThe underlying genetic cause of the cancer is the most important determinant of how the cancer evolves and how it responds to therapy. There is currently no known cure for leukemia. There are some targeted therapies that have been shown to improve the outcomes for patients." - Anonymous Online Contributor
"There is no single factor that accounts completely for the development of leukemia. Rather, factors that are present in leukemia are often found in combination. This suggests that several factors must be involved in the development of leukemia.\n" - Anonymous Online Contributor
"In 2002, around 22,000 people in the US had leukemia of all types. This is around 1.2% of the US adult population. Although childhood leukemias made up 57% of all leukemias, they represent only 4% of the US adult leukemias. The average age at diagnosis is 67 years for both children and adult leukemias. The overall 5-year survival rate is 73% in children with leukemia and 76% in adults (1997). In adults, the 5-year overall survival rate is 91% for acute leukemia, 59% for chronic lymphocytic leukemia, and 67% for chronic myeloid leukemia." - Anonymous Online Contributor
"The data demonstrates the high efficacy of daily dosage of umbralisib compared to placebo with favorable clinical outcome. Due to the short period on treatment, it was not able to determine the clinical efficacy of the therapy beyond a short time. Findings from a recent study support further clinical evaluation and optimization of the new drug umbralisib for the treatment of leukemia"
"Dendrophilia pudens\n\nDendrophilia pudens is a moth of the family Gelechiidae. It was described by Walsingham in 1909. It is found in Mexico (Tabasco)." - Anonymous Online Contributor
"The latest information on leukemia was found on an NIH site where scientists, in order to study different blood diseases, have collaborated to study leukemia and work on new treatments for cancer and leukemia. It is necessary that our research should be done in research labs where we find new medicines not only in the field of research that we have already mentioned in the beginning of this article, but to find a way to treat the disease. To discover drugs that work in vivo should be the ultimate goal in science, because it would help save lots of dead leukemia patients, in addition to the current research that we have done here in this article will help in finding medicines for treatment of leukemia for future generations." - Anonymous Online Contributor
"The common side effects of umbralisib are headache (40%), diarrhea (39%), fatigue (36%), nausea (26%), and peripheral edema (20%). Some side effects, such as fatigue, headache, and dizziness, occur in high incidence and most are Grade 1 or Grade 2 (defined as Grade 1 when severity grade rating ≤ 2 and Grade 2 when severity grade rating > 2 and > 5% when occurring in ≥10% of patients). Most severe side effects are Grade 3 and all occur in ≤10% of patients (Grade 3 in ≤ 2% and Grade 3 in 0.1% when occurring in ≥10% of patients)." - Anonymous Online Contributor
"Trial eligibility is a complex issue, based on our analysis on existing studies. Physicians should consider their patients individually, because they have specific characteristics affecting clinical trial eligibility." - Anonymous Online Contributor
"These data raise concern of the possible increased toxicity and mortality associated with the use of umbralisib in combination with other treatments. Clinicians should carefully monitor such patients during treatment." - Anonymous Online Contributor
"Umbralisib improved quality of life in children with acute leukemia, including improvement in the number of days without neutropenia. Umbralisib was well-tolerated, especially with dosing schedules of 2 or 3 days per week." - Anonymous Online Contributor